Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.

Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S.

Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1065-71.

PMID:
17674425
2.

Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

Krentz A.

Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Review.

PMID:
19219860
3.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Review.

PMID:
18698014
4.
5.

[Therapy with glitazones--a risk for cardiovascular disease?].

Rottlaender D, Michels G, Erdmann E, Hoppe UC.

Dtsch Med Wochenschr. 2007 Dec;132(49):2629-32. Review. German.

PMID:
18050028
6.

Cardiovascular risk and cardiometabolic protection: role of glitazones.

Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri C.

J Nephrol. 2008 Nov-Dec;21(6):826-35. Review.

PMID:
19034866
7.

Reassessing the cardiovascular risks and benefits of thiazolidinediones.

Zinn A, Felson S, Fisher E, Schwartzbard A.

Clin Cardiol. 2008 Sep;31(9):397-403. doi: 10.1002/clc.20312. Review.

8.

The safety of rosiglitazone in the treatment of type 2 diabetes.

Singh S, Loke YK.

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 . Review.

PMID:
18759710
9.

The cardiovascular safety of rosiglitazone.

Ajjan RA, Grant PJ.

Expert Opin Drug Saf. 2008 Jul;7(4):367-76. doi: 10.1517/14740338.7.4.367 . Review.

PMID:
18613801
10.

Rosiglitazone and cardiovascular risk.

Kaul S, Diamond GA.

Curr Atheroscler Rep. 2008 Oct;10(5):398-404. Review.

PMID:
18706281
11.

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N.

Diabetes Obes Metab. 2008 Dec;10(12):1221-38. doi: 10.1111/j.1463-1326.2008.00892.x. Review.

PMID:
18505403
12.

Cardiovascular risk of rosiglitazone: another perspective.

Waksman JC.

J Pharm Pharmacol. 2008 Dec;60(12):1573-82. doi: 10.1211/jpp.60.12.0002. Review.

PMID:
19000361
13.

Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?

Doggrell SA.

Expert Opin Pharmacother. 2008 Feb;9(3):405-20. doi: 10.1517/14656566.9.3.405 . Review.

PMID:
18220491
14.

[Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].

De Flines J, Scheen AJ.

Rev Med Suisse. 2007 Aug 29;3(122):1876, 1878-83. Review. French.

PMID:
17896661
15.

Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis.

Singh S, Loke YK, Furberg CD.

Thorax. 2011 May;66(5):383-8. doi: 10.1136/thx.2010.152777. Review.

PMID:
21325145
16.

The rosiglitazone meta-analysis.

McCullough PA, Lepor NE.

Rev Cardiovasc Med. 2007 Spring;8(2):123-6. Review. No abstract available. Erratum in: Rev Cardiovasc Med. 2007 Summer;8(3):174.

PMID:
17603430
17.

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

Loke YK, Kwok CS, Singh S.

BMJ. 2011 Mar 17;342:d1309. doi: 10.1136/bmj.d1309. Review.

18.

Supplemental Content

Support Center